Filed: 11/14/2024ACC: 0001172661-24-004815
📋 What this filing means
VANTAGE CONSULTING GROUP INC filed this quarterly 13F‑HR report disclosing 4 equity positions with a total reported market value of $11.42M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
4
Positions
$11.42M
Total AUM (reported)
4.61M
Total Shares
Allocation by class
COM$5.01M43.9%
CL A COM STK$3.73M32.7%
SHS$2.68M23.5%
Portfolio Concentration
Top 3$11.34M99.3%
4–10$78.2K0.7%
Top 3 weight
99.3%
Top 10 weight
100.0%
Voting Authority Distribution
Total shares with voting rights: 4.61M
Sole
Full voting authority
4.61M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole4
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings4
Rows:
BABCOCK & WILCOX ENTERPRISES
SOLEShares2.42M
TypeSH
Market value$4.93M
43.18%
Sole
2.42M
Shared
0.00
None
0.00
CIBUS INC
SOLEShares1.14M
TypeSH
Market value$3.73M
32.67%
Sole
1.14M
Shared
0.00
None
0.00
ADC THERAPEUTICS SA
SOLEShares850.74K
TypeSH
Market value$2.68M
23.47%
Sole
850.74K
Shared
0.00
None
0.00
FIBROGEN INC
SOLEShares195.71K
TypeSH
Market value$78.2K
0.68%
Sole
195.71K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
BABCOCK & WILCOX ENTERPRISESSOLE | COM | 2.42M | SH | $4.93M 43.18% | 2.42M | 0.00 | 0.00 |
CIBUS INCSOLE | CL A COM STK | 1.14M | SH | $3.73M 32.67% | 1.14M | 0.00 | 0.00 |
ADC THERAPEUTICS SASOLE | SHS | 850.74K | SH | $2.68M 23.47% | 850.74K | 0.00 | 0.00 |
FIBROGEN INCSOLE | COM | 195.71K | SH | $78.2K 0.68% | 195.71K | 0.00 | 0.00 |